Green tea and type 2 diabetes

Jae-Hyung Park, Jae-Hoon Bae, Sung-Soon Im, Dae-Kyu Song *

Department of Physiology, Keimyung University School of Medicine, Daegu, Korea

ABSTRACT

Green tea and coffee consumption have been widely popular worldwide. These beverages contain caffeine to activate the central nervous system by adenosine receptor blockade, and due to the caffeine, addiction or tolerance may occur. In addition to this caffeine effect, green tea and coffee consumption have always been at the center of discussions about human health, disease, and longevity. In particular, green tea catechins are involved in many biological activities such as antioxidation and modulation of various cellular lipid and proteins. Thus, they are beneficial against degenerative diseases, including obesity, cancer, cardiovascular diseases, and various inflammatory diseases. Some reports also suggest that daily consumption of tea catechins may help in controlling type 2 diabetes. However, other studies have reported that chronic consumption of green tea may result in hepatic failure, neuronal damage, and exacerbation of diabetes, suggesting that interindividual variations in the green tea effect are large. This review will focus on the effect of green tea catechins extracted from the Camellia sinensis plant on type 2 diabetes and obesity, and the possible mechanistic explanation for the experimental results mainly from our laboratory. It is hoped that green tea can be consumed in a suitable manner as a supplement to prevent the development of type 2 diabetes and obesity.

© 2014 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Green tea is now consumed everywhere as a beverage and is a remedy to prevent some degenerative diseases. However, the effectiveness of green tea consumption on diseases has not been clearly demonstrated in humans, although many animal experiments have shown positive results. Green tea extract (GTE) has many naturally occurring biological components of which polyphenolic epicatechins (ECs) are predominantly active (Fig. 1). These include (−)-epigallocatechin-3-gallate (EGCG), (−)-epigallocatechin (EGC), (−)-epicatechin-3-gallate (ECG), and (−)-EC. The EC and EGC are catechol catechins, EGC and EGCG are pyrogallol catechins, and ECG and EGCG are gallate catechins. This review focuses on the effect of EGCG on diabetes and obesity. The first section describes the overall effect of EGCG on diabetes and obesity, and the second part is an analysis of the effect of EGCG on degenerative metabolic diseases.
diabetes-related parameters, including blood glucose levels, HbA1C levels, insulin resistance, and inflammation markers. Many randomized trials support this result of Fukino et al. However, some retrospective cohort studies in Japan and Taiwan suggest that green tea is effective against type 2 diabetes.

Those studies revealed that EGCG, the most abundant form of catechin in green tea, inhibits adipocyte proliferation and differentiation, increases cellular defense against oxidative stress, and blocks sodium-dependent glucose transporter 1 (SGLT1) and lipid micelle formation in the intestine. However, the concentrations of EGCG required to decrease the number of preadipocytes and adipocytes are too high to be consumed by humans without considerable side effects. Although green tea catechins have the molecular structure to scavenge oxygen-free radicals, their effectiveness in biological systems has not been clarified. Some reports demonstrate that EGCG is a pro-oxidant and harmful for beta-cell survival in streptozotocin-induced diabetic rats. Blockage of SGLT1 and lipid micelle formation is the most important and strongest mechanism for gallate catechins to exert their effects against obesity and diabetes. However, there is a limitation to use gallate catechins as a remedy for these two metabolic diseases. A lower concentration of gallate catechins than those that block SGLT1 blocks sodium-independent glucose transporters (GLUTs) in various tissues. Although dietary glucose absorption into the circulation is mainly performed by intestinal SGLT1 as well as by some GLUTs, cellular glucose uptake as an energy source in most cells is performed by insulin-dependent (GLUT4) and insulin-independent GLUTs. Maximum blood EGCG concentrations are achieved 90 minutes after green tea ingestion and considerable concentrations of EGCG are present in circulation for 3–4 hours. This means that the effects of EGCG in the alimentary tract remain only for 1 hour, but the effects in circulation remain for several hours. Blocking cellular glucose uptake during the postprandial period resembles insulin resistance, eventually leading to failure of beta cells to secrete more insulin.

The discrepancy among human epidemiological data for the antidiabetogenic effects of green tea catechins can be attributed to several reasons. As shown in Table 1, one cup of green tea contains approximately 100 mg EGCG in 1 g GTE. This quantity easily makes blood concentrations of EGCG about 100 nM in a fasting state, and a concentration that can inhibit various GLUTs. In addition, there are significant interindividual variations in blood concentrations of EGCG after green tea ingestion, suggesting that there are difficulties in

| Species variation in the amount of EGCG to be absorbed into circulation after IG ingestion of EGCG* |
|---------------------------------|-----------------|----------------|---|
| IG ingestion of EGCG | Blood concentrations | Refs |
| Rat | 75 mg/kg | 35 nM | 21 |
| Mouse | 75 mg/kg | 280 nM | 22 |
| Human | 2 mg/kg | 170 nM | 20 |
| | 525 mg in GTE/man | 4.4 μM | 19 |

* A cup of green tea contains approximately 100 mg EGCG in 1 g GTE. EGCG, (–)-epigallocatechin-3-gallate; GTE, green tea extract; IG, intragastric.
controlling EGCG concentration in experiments involving humans, as the meals make absorption of the GTE slower. By contrast, animal experiments are more controllable and show that rats have the lowest oral bioavailability of EGCG compared with mice and humans (Table 1); in fact, the oral bioavailability of EGCG is lower in mice than that in humans. Therefore, during animal experiments, oral ingestion of GTE or EGCG only shows the intestinal effects but not the effect in circulation. Thus, the results may be more interpreted as positive results against obesity and diabetes than those obtained from humans. Therefore, to extend the intestinal effects of EGCG and to decrease the circulatory effect of EGCG, entry of EGCG into circulation should be blocked, at least for using EGCG to treat type 2 diabetes and obesity.

3. EGCG effect in metabolic tissues

3.1. How much green tea should we take for the intestinal effect of EGCG?

Kobayashi et al. found that the 50% inhibitory concentration (Ki) of ECG to block 50% of rabbit intestinal glucose uptake was 390 μM. Park et al. reported that the 50% inhibition of glucose uptake was around 100 μM for EGCG in the human colon adenocarcinoma CACO-2 cells, whereas an inhibitory effect was observed at 10 μM. Concentrations of EGCG > 100 μM are necessary to block lipid micelle formation. Further found that 500-mg EGCG/kg body weight is necessary to inhibit 50% cholesterol absorption in rats. Park et al. reported that the EGCG effect can be potentiated if EGCG is applied as a constituent of an intact GTE, as other GTE constituents protect EGCG from degradation or ECG adds the same effect as EGCG. Use of GTE, not EGCG, is a means to reduce the amount of EGCG used. GTE containing at least 100 mg EGCG may be necessary to exert an effect on SGLT1 and lipid micelle formation in the gastrointestinal tract. Fortunately, this level would not block amino acid and polypeptide transporters in the intestine. Therefore, it would be sufficient to have one cup of green tea just prior to a meal. However, as shown in Tables 1 and 2, plasma concentrations of EGCG could easily reach 100 nM with normal daily consumption of green tea, which is a concentration that would inhibit various GLUTs in tissues and lead to a shortage of glucose in cells. This is a burden on beta cells and glucose-deficient cells to decrease blood glucose levels during the postprandial period.

| Table 2 – Dose-dependent effects of EGCG | Concentrations, μM | Refs | Catechins |
|----------------------------------------|--------------------|------|-----------|
| **Functions**                           |                    |      |           |
| SGLT1 block                            | >1                 | 23   | <ECG      |
| GLUTs block                            | <1                 | 13   | <ECG      |
| Micelle formation block                | >100               | 14   | ≈ECG (probably) |
| Alcohol absorption block               | >100               | 23   | ≈ECG (only GC) |
| **In K_ATP channels**                  |                    |      |           |
| PIPs sensitivity block                 | <1                 | 48   | only EGC  |
| ATP sensitivity block                  | >1                 | 48   | only EGC  |
| Direct channel block                   | >10                | 46   | >EGC, <ECG |
| **In adipocytes**                      |                    |      |           |
| Increased RBP-4 secretion              | >1                 | 15   | >ECG      |
| Increased ROS generation               | >10                | 15   | >ECG      |
| Decreased adipocyte survival           | >10                | 15   | >ECG      |
| Decreased PPAR-γ expression            | >10                | 15   | >ECG      |
| Decreased adiponectin expression       | >10                | 15   | >ECG      |

ATP, adenosine triphosphate; ECG, (−)-epicatechin-3-gallate; EGC, (−)-epigallocatechin; EGCG, (−)-epigallocatechin-3-gallate; GC, gallatecatechin; GLUTs, glucose transporters; K_ATP, ATP-sensitive K+; PIPs, phosphatidylinositol polyphosphates; PPAR-γ, peroxisome proliferator-activated receptor-γ; RBP-4, retinol binding protein-4; ROS, reactive oxygen species; SGLT1, sodium-dependent glucose transporter 1.
with vitamin E and EGCG, suggesting that increased ROS generation could be a factor for EGCG-induced RBP-4 upregulation. The increased expression of RBP-4 after EGCG treatment was further recovered by co-treatment of methyl pyruvate with vitamin E, which is a cellular energy source bypassing GLUTs and glycolysis, suggesting that impaired glucose uptake by EGCG was also a causative mechanism for RBP-4 upregulation. Secretion of RBP-4 in human adipocytes consistently increased with 10 μM EGCG, which is lower than the 50 μM EGCG required to induce intracellular ROS accumulation. This observation suggests that the ROS-independent mechanism to block glucose uptake can be another critical factor to increase RBP-4 expression and secretion. Thus, long-term application of lower EGCG concentrations could increase RBP-4 signaling. The EGCG concentration dependency of intracellular ROS accumulation in adipocytes in our study was consistent with other findings.18,29,30 Unfortunately, EGCG-induced ROS generation at the higher EGCG concentration does not show tissue specificity.17,30-32 If it was tissue specific, it would be useful for obesity to target only adipocytes or for certain localized cancers. In addition, higher concentrations of EGCG are not achievable in human plasma without considerable adverse effects.33 Therefore, the pro-oxidative nature of high concentrations of EGCG is not an acceptable mechanism to protect against obesity and even cancers. There are reports describing EGCG concentration dependency in the EGCG-oxidative stress relationship; nanomolar concentrations of EGCG have an antioxidant action and micromolar concentrations of EGCG have a pro-oxidant action. However, the pro-oxidative activity of EGCG can occur at concentrations < 50 μM, even at about 1 μM concentration in the beta cells damaged previously by streptozotocin18 or hippocampal neuronal cells.17 This suggests that EGCG always induces ROS stress in cells that would not occur if the cell's scavenging systems are intact. Therefore, EGCG action against oxygen-free radicals may be altered by the kinds of radical stimulants, cellular conditions, and the exposed time to EGCG. Green tea catechins can exert their effect as both pro-oxidants and antioxidants;12,35 the presence of the gallate (G) ring, the catechol (C) ring, the pyrogallol (P) ring, or the resorcinol (R) ring is important for the antioxidant activities of catechins.36 In addition, the P ring is also important for the antifungal action of catechins.36 The pro-oxidative activity of catechins is attributed to their potency from auto-oxidation and peroxidase-catalyzed oxidation.37 As previously noted, the potency of increasing ROS in adipocytes is EGCG > ECG, but not nongallate catechins, of which EGCG has both pyrogallol and gallate moieties.

3.3. EGCG on cellular glucose uptake

We think that a critical factor to increase RBP-4 secretory signaling from mature adipocytes is the effect of EGCG to decrease cellular glucose uptake. It is well known that cellular glucose uptake in various tissues is impaired in the insulin-resistance state, making beta cells secrete more insulin and causing early beta-cell exhaustion throughout life. Impaired glucose uptake by EGCG can be observed at EGCG concentrations < 10 μM.38 Park et al.24 also showed that EGCG inhibits cellular glucose uptake at 100 nM in myocytes, adipocytes, and beta cells, and 1 μM in hepatocytes, which is easily achievable in human plasma by oral intake of two to three cups of green tea24 (Table 1). These findings are consistent with the results obtained in other tissues by previous observations.16,39,40 suggesting that most tissues possessing either of various GLUTs can be hindered with glucose use in the presence of EGCG. The adipokine RBP-4 is secreted from mature adipocytes when adipocytes detect deficient glucose uptake.31 In the fasting state, secretion of RBP-4 stimulates hepatic glucose output and inhibits muscular glucose uptake, probably to spare blood glucose levels. Therefore, abnormally increased expression and secretion of RBP-4 may elicit insulin resistance. It would be difficult to normalize blood glucose levels by insulin during the postprandial period if plasma EGCG hinders most tissues to uptake glucose. This action of EGCG on GLUTs may be related to its gallate moiety, because ECG and genistein also have a blocking effect toward GLUTs, and ECG is the more potent.31,39 The mechanism of EGCG to inhibit cellular glucose uptake may be either blockade of insulin signaling or direct competition with glucose for GLUTs.43 We found that insulin-induced Ser473 phosphorylation of protein kinase B remained unchanged in the presence of EGCG in hepatocytes, adipocytes, myocytes, and beta cells.34 The impact of this EGCG action on cellular glucose uptake can be observed in vivo and we found that EGCG at about 1 μM in blood acutely elevates blood glucose and insulin levels during the oral glucose tolerance test (OGTT) in humans.24 It confirms that daily intake of green tea is clinically relevant. We orally applied GTE-containing EGCG at about 100 mg to selected human participants either immediately or 1 hour prior to oral glucose ingestion for the OGTT. In the former case, blood glucose levels during the OGTT were maintained lower than the control without GTE ingestion. However, in the latter, blood glucose and insulin levels were greater than those in the control. In addition, greater insulin resistance was observed during the insulin tolerance test. This finding was also true for ECG, and a gallate catechin-free GTE would not exert this effect. This result clearly suggests that absorbed gallate catechins, mainly EGCG and ECG, hinder cellular glucose uptake in insulin-sensitive tissues during the OGTT and thus increase insulin secretion from beta cells. This phenomenon occurring by ingesting the GTE is well matched with the postprandial period in prediabetes with insulin resistance and overt type 2 diabetes. We further confirmed that this EGCG action was not associated with the effect of EGCG on adenosine triphosphate (ATP)-sensitive K+ (KATP) channels because it occurred even in KATP channel-deficient mice.

3.4. Direct KATP channel modulation of EGCG

The plasmalemmal KATP channel is an octamer that includes four inwardly rectifying potassium (Kir)6.2 and four sulfonylurea receptors (SURs). EGCG inhibits the activity of Kir6.2/SUR1 (beta-cell type) in Xenopus oocytes expressing KATP channels, with an inhibitory concentration 50 (IC50) of about 140 μM, which is also observed in Kir6.2/SUR2A (cardiac type) and Kir6.2/SUR2B (vascular type). The inhibitory potency of EGCG was similar to the IC50 of EGCG for voltage-dependent potassium (KV) 1.5 channels (101 μM).44 ECG is three times more effective for this inhibition than EGCG, and nongallate
catechins did not have any effect. The IC50 of EGCG for channel inhibition was about 20 μM with Kir6.2ΔC36 channels, which are the channel pore-forming subunits. The absence of the SUR subunits suggests that the regulatory subunit SUR may hinder the inhibitory action of EGCG on Kir6.2. The principal mechanism for Kir6.2 blockade of gallate catechins may be due to the interaction between EGCG and ECG with lipid bilayers embedded in the KATP channels, because the interaction of catechins with lipids is stronger when the catechol ring and gallate ring are both present as in ECG. A small contribution of the pyrogallol ring is also detected because EGC can inhibit KATP channels, but only slightly.

3.5. **EGCG-induced change in KATP channel sensitivity to phosphatidylinositol polyphosphates and ATP**

The KATP channel activity is inhibited by ATP through the Kir6.2 subunit and activated by MgADP through the SUR subunit. Phosphatidylinositol polyphosphates (PIPs) such as PIP2 and PIP3 activate the channel through the Kir6.2. The KATP channels play crucial roles in glucose-stimulated insulin secretion in beta cells and protect cardiac myocytes from metabolic inhibition. Although direct KATP channel inhibition was accomplished by gallate catechins such as EGCG and ECG, the reducing effect of the GTE on KATP channel ATP and PIP sensitivity only occurred in EGCG, which additionally has the hydroxyl group (-OH) on the pyrogallol moiety. The ATP sensitivity of the KATP channel in the presence of 10 μM EGCG was 10 times less than that in the absence of EGCG (13.4 μM vs. 120 μM). EGCG did not eliminate the bound ATP molecules from the channels but inhibited channel binding of ATP. The adenosine monophosphate (AMP) and adenosine diphosphate blocks for KATP channels were not hindered by EGCG. The γ-phosphate tail of ATP is bound to R50 in the N terminal of Kir6.2, and ATP binding to Kir6.2 is facilitated by incorporating SUR1. Our results show that EGCG may inhibit the facilitating function of SUR1. Moreover, the decrease in the channel PIP sensitivity caused by EGCG appears even at 1 μM EGCG. This may have occurred due to direct hindrance of the PIP interactions with their binding sites on Kir6.2 by EGCG. The mechanism may be due to the negative charges of EGCG and the positive charges on the PIP binding sites of the channels against the negative charges of PIPs. It would require a serious involvement of EGCG in KATP channel gating kinetics if the two major modulators ATP and PIPs have a limitation to play their actions.

4. **Concluding remarks and future perspectives**

The effects of EGCG regarding diabetes and obesity are summarized in Table 2 and the related molecular structures of...
EGCG are shown in Table 3. The antioxidative effects of green tea can be a substitute for other well-known antioxidants. Blockage of adipocyte differentiation and proliferation by EGCG is not possible in humans because intolerable plasma concentrations of EGCG are required. Animal data considering the effect of EGCG on obesity and diabetes cannot be replicated in humans because of different oral bioavailability among species. Green tea intake to exert beneficial intestinal effects sufficiently elevates blood EGCG levels to inhibit cellular glucose uptake. Many previous in vitro experimental data show the downstream phenomena for the effect of EGCG on inhibiting cellular glucose uptake, such as elevated AMP-activated protein kinase activity. EGCG may be effective for cancer protection due to its inhibitory action on cancer-cell glucose utilization, but not by direct modulation of specific cellular signaling. Blocking the absorption of green tea gallate catechins, which block cellular glucose uptake in the circulation, may be a clue for green tea use against diabetes and obesity. This also means prolongation of their effects in the intestine. Polyethylene glycol-3350 or poly-γ-glutamate dramatically and selectively block entry of gallate catechins into circulation, prolonging their intestinal effects (Fig. 2).23–25 Human clinical trials should proceed to develop a safer treatment tool against type 2 diabetes and related obesity.

Conflicts of interest

All contributing authors declare no conflicts of interest.

Acknowledgments

This study was supported by iPET (Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries), Ministry for Food, Agriculture, Forestry, and Fisheries, Republic of Korea (Grant No. 110135-3).

REFERENCES

1. Fukino Y, Shimbo M, Aoki N, Okubo T, Iso H. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. J Nutr Sci Vitaminol (Tokyo) 2005;51:335–42.
2. Mackenzie T, Leary L, Brooks WB. The effect of an extract of green tea on glucose control in adults with type 2 diabetes mellitus: double-blind randomized study. Metabolism 2007;56:1340–4.
3. Nagao T, Meguro S, Hase T, Otsuka K, Komikado M, Tokimitsu I, et al. A catechin-rich beverage improves obesity and blood glucose control in patients with type 2 diabetes. Obesity (Silver Spring) 2009;17:310–7.
4. Hsu CH, Liao YL, Lin SC, Tsai TH, Huang CJ, Chou P. Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. Altern Med Rev 2011;16:157–63.
5. Ryu OH, Lee J, Lee KW, Kim HY, Seo JA, Kim SG, et al. Effects of green tea consumption on inflammation, insulin resistance and pulse wave velocity in type 2 diabetes patients. Diabetes Res Clin Pract 2006;71:356–8.
6. Anderson RA, Polansky MM. Tea enhances insulin activity. J Agric Food Chem 2002;50:7182–6.
7. Iso H, Date C, Wakai K, Fukui M, Tamakoshi A, JACC Study Group. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann Intern Med 2006;144:554–62.
8. Wu CH, Lu FH, Chang CS, Chang TC, Wang RH, Chang CJ. Relationship among habitual tea consumption, percent body fat, and body fat distribution. Obes Res 2003;11:1088–95.
9. Hung PF, Wu BT, Chen HC, Chen YH, Chen CL, Wu MH, et al. Antimitogenic effect of green tea (–)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the ERK and Cav2 pathways. Am J Physiol Cell Physiol 2005;288. C1094–C108.
10. Wang CT, Chang HH, Hsiao CH, Lee MJ, Ku HC, Hu YJ, et al. The effects of green tea (–)-epigallocatechin-3-gallate on reactive oxygen species in 3T3-L1 preadipocytes and adipocytes depend on the glutathione and 67 kDa laminin receptor pathways. Mol Nutr Food Res 2009;53:349–60.
11. Wu BT, Hung PF, Chen HC, Huang RN, Chang HH, Kao YH. The apoptotic effect of green tea (–)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the Cav2 pathway. J Agric Food Chem 2005;53:5695–701.
12. Mukai K, Nagai S, Ohara K. Kinetic study of the quenching reaction of singlet oxygen by tea catechins in ethanol solution. Free Radic Biol Med 2005;39:752–61.
13. Kobayashi Y, Suzuki M, Satus H, Arai S, Hara Y, Suzuki K, et al. Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. J Agric Food Chem 2000;48:5618–23.
14. Raederstorff DG, Schlachter MF, Elste V, Weber P. Effect of EGCG on lipid absorption and plasma lipid levels in rats. J Nutr Biochem 2003;14:326–32.
15. Sung HY, Hong CG, Suh YS, Cho HC, Park JH, Bae JH, et al. Role of (–)-epigallocatechin-3-gallate in cell viability, lipogenesis, and retinol-binding protein 4 expression in adipocytes. Naunyn Schmiedebergs Arch Pharmacol 2010;382:303–10.
16. Naftalin RJ, Azfai I, Cunningham P, Halai M, Ross C, Salleh N, et al. Interactions of androgens, green tea catechins and the antiandrogen flutamide with the external glucose-binding site of the human erythrocyte glucose transporter GLUT1. Br J Pharmacol 2003;140:487–99.
17. Yin ST, Tang ML, Deng HM, Xing TR, Chen JT, Wang HL, et al. Epigallocatechin-3-gallate induced primary cultures of rat hippocampal neurons death linked to calcium overload and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol 2009;379:551–64.
18. Yun SY, Kim SP, Song DK. Effects of (–)-epigallocatechin-3-gallate on pancreatic beta-cell damage in streptozotocin-induced diabetic rats. Eur J Pharmacol 2006;541:115–21.
19. Nakagawa K, Okuda S, Miyazawa T. Dose-dependent incorporation of tea catechins, (–)-epigallocatechin-3-gallate and (–)-epigallocatechin, into human plasma. Biosci Biotechnol Biochem 1997;61:1981–5.
20. Lee MJ, Maliaakal P, Chen L, Meng X, Bondoc FY, Prabhu S, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (–)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Preu 2002;11:1025–32.
21. Chen L, Lee MJ, Li H, Yang CS. Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos 1997;25:1045–50.
22. Lambert JD, Yang CS. Mechanisms of cancer prevention by tea constituents. J Nutr 2003;133, 3262S–7S.
23. Park JH, Choi YJ, Kim YW, Kim SP, Cho HC, Ahn S, et al. Green tea extract with polyethylene glycol-3350 reduces body weight and improves glucose tolerance in db/db and...
high-fat diet mice. Naunyn Schmiedebergs Arch Pharmacol 2013;386:733–45.

24. Park JH, Jin JY, Baek WK, Park SH, Sung HY, Kim YK, et al. Ambivalent role of gallated catechins in glucose tolerance in humans: a novel insight into non-absorbable gallated catechin-derived inhibitors of glucose absorption. J Physiol Pharmacol 2009;60:101–9.

25. Bae KC, Park JH, Na AY, Kim SJ, Ahn S, Kim SP, et al. Effect of green tea extract/poly-γ-glutamic acid complex in obese type 2 diabetic mice. Diabetes Metab J 2013;37:196–206.

26. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.

27. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29–33.

28. Lin J, Della-Fera MA, Baile CA. Green tea polyphenol epigallocatechin gallate inhibits adipogenesis and induces apoptosis in 3T3-L1 adipocytes. Obes Res 2005;13:982–90.

29. Moon HS, Chung CS, Lee HG, Kim TG, Choi YJ, Cho CS. Inhibitory effect of (–)-epigallocatechin-3-gallate on lipid accumulation of 3T3-L1 cells. Obesity (Silver Spring) 2007;15:2571–82.

30. Yu Q, Li W, Nie S, Xie M. (–)-Epigallocatechin-3-gallate induces apoptosis of human hepatoma cells by mitochondrial pathways related to reactive oxygen species. J Agric Food Chem 2009;57:6685–91.

31. Morikawa K, Ikeda C, Nonaka M, Pei S, Mochizuki M, Mori A, et al. Epigallocatechin gallate-induced apoptosis does not affect adipocyte conversion of preadipocytes. Cell Biol Int 2007;31:1379–87.

32. Sakurai N, Mochizuki K, Kameji H, Shimada M, Goda T. Epigallocatechin gallate induces differentiation in 3T3-L1 adipocytes at an early stage of differentiation. Nutrition 2009;25:1047–56.

33. Chow HH, Albers DS, Hakim I, Dorr R, Shahi F, et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 2001;10:53–8.

34. Salah N, Miller NJ, Paganga G, Tijburg L, Bolwell GP, Rice-Evans C. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophys 1995;322:339–46.

35. Oikawa S, Furukawaa A, Asada H, Hirakawa K, Kawanishi S. Catechins induce oxidative damage to cellular and isolated DNA through the generation of reactive oxygen species. Free Radic Res 2003;37:881–90.